Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a
global leader in cell therapy, today reported financial results for
the fourth quarter and year ended December 31, 2024, and key
corporate highlights.
“We are coming off a tremendously successful
year. Our 2024 total revenue nearly achieved blockbuster status,
and we are just now building out our many opportunities with
CARVYKTI. There are more milestones ahead that will potentially
make CARVYKTI available to even more patients,” said Ying Huang,
Ph.D., Chief Executive Officer of Legend Biotech. “CARVYKTI has
already helped thousands of multiple myeloma patients. Even though
CARVYKTI is the market leader for CAR-T in multiple myeloma, we are
still working relentlessly to elevate our commercial,
manufacturing, regulatory and clinical efforts. While we are
focused on executing with excellence for CARVYKTI this year, we
continue to prioritize the right investments to enhance our
opportunities as a stand-alone cell therapy company for the long
term.”
Key Business Developments
- Treated over 5,000 clinical and
commercial patients to date.
- Announced positive three-year
follow-up data from the Phase 3 CARTITUDE-4 study showing that
CARVYKTI® increased the minimal residual disease (MRD) negativity
rates when compared to the standard of care for patients with
relapsed or refractory multiple myeloma. In the study, 89 percent
of evaluable patients achieved MRD negativity at the 10-5
threshold, with the majority of patients achieving MRD negativity
in less than two months.
- In the first quarter of 2025,
initiated commercial production of CARVYKTI® at a Novartis
production facility pursuant to the master manufacturing and supply
agreement among Legend, Janssen, and Novartis.
- Spain's national health system,
Sistema Nacional de Salud (“SNS”), approved reimbursement for
CARVYKTI® for the treatment of adult patients with relapsed and
refractory multiple myeloma who have received at least one prior
line of treatment, including an immunomodulatory agent and a
proteasome inhibitor, have demonstrated disease progression after
the last treatment and are refractory to lenalidomide.
- Cash and cash equivalents, and time
deposits of $1.1 billion, as of December 31, 2024, which
Legend Biotech believes will provide financial runway into the
second quarter of fiscal year 2026, when Legend Biotech anticipates
potentially achieving an operating profit excluding unrealized
foreign exchange gains or losses.
Financial Results for Quarter and Year Ended
December 31, 2024
Cash and Cash Equivalents, and Time
Deposits
As of December 31, 2024, Legend Biotech had
approximately $1.1 billion of cash and cash equivalents and time
deposits.
Revenue
License RevenueThere was
$18.3 million license revenue for the three months ended
December 31, 2024, and no license revenue for
December 31, 2023. This increase of $18.3 million was
primarily driven by the license revenue recognized in 2024 pursuant
to Legend Biotech’s license agreement with Novartis for the
development, manufacture, and commercialization of LB2102 and other
potential CAR-T therapies selectively targeting DLL-3 (the
“Novartis License Agreement”), and since the license agreement was
effective as of December 28, 2023, no license revenue was
recognized in 2023. License revenue for the year ended
December 31, 2024, was $138.4 million, compared to
$35.2 million for the year ended December 31, 2023. This
increase of $103.2 million was primarily driven by the license
revenue recognized in 2024 pursuant to the Novartis License
Agreement, as well as the nature and timing of milestones achieved
as outlined under the Janssen Agreement for cilta-cel.
Collaboration
RevenueCollaboration revenue for the three months and year
ended December 31, 2024, was $168.0 million and
$482.6 million, respectively, compared to $79.4 million
and $249.8 million for the three months and year ended
December 31, 2023, respectively. The increase of
$88.6 million and $232.8 million for the three months and
year ended, respectively, was due to an increase in revenue
generated from sales of CARVYKTI® in connection with the Janssen
Agreement.
Other RevenueOther revenue for
the three months and year ended December 31, 2024, was
$0.2 million and $6.3 million, respectively, compared to
$0.0 million and $0.2 million for the three months and
year ended December 31, 2023, respectively. Other revenue
primarily includes payments made in connection with the supply of
materials by us to Novartis under the terms of the Novartis License
Agreement.
Operating Expenses
Cost of Collaboration
RevenueCost of collaboration revenue for the three months
and year ended December 31, 2024, was $69.4 million and
$216.4 million, respectively, compared to $32.5 million and $144.2
million for the three months and year ended December 31, 2023,
respectively. The increase of $36.9 million and
$72.2 million for the three months and year ended,
respectively, were due to a combination of Legend Biotech’s share
of the cost of sales in connection with CARVYKTI® sales under the
Janssen Agreement and expenditures to support expansion in
manufacturing capacity.
Cost of License and Other
RevenueCost of license and other revenue for the three
months and year ended December 31, 2024, was $4.5 million
and $18.2 million, respectively, and consisted of costs in
connection with the Novartis License Agreement. The Company did not
incur any costs of license and other revenue for the three months
and year ended December 31, 2023.
Research and Development
ExpensesResearch and development expenses for the three
months and year ended December 31, 2024, were $104.4 million
and $413.5 million, respectively, compared to $105.7 million and
$382.2 million for the three months and year ended
December 31, 2023, respectively. The increase of
$31.3 million for the year ended was primarily due to research
and development activities in cilta-cel, including start-up costs
for clinical production in Belgium, as well as continued investment
in our solid tumor programs.
Administrative
ExpensesAdministrative expenses for the three months and
year ended December 31, 2024, were $34.2 million and $136.8
million, respectively, compared to $28.7 million and $106.8 million
for the three months and year ended December 31, 2023,
respectively. The increase of $5.5 million and
$30.0 million for the three months and year ended,
respectively, was primarily due to the expansion of administrative
functions and the additional headcount needed to provide
administrative support as a result of the company's expanded
infrastructure, driven by increased manufacturing capacity.
Selling and Distribution
ExpensesSelling and distribution expenses for the three
months and year ended December 31, 2024, were $48.9 million
and $147.5 million, respectively, compared to $33.7 million
and $94.2 million for the three months and year ended
December 31, 2023, respectively. The increase of
$15.2 million and $53.3 million for the three months and
year ended, respectively was primarily driven by an increase in
costs associated with commercial activities for cilta-cel,
including the expansion of the sales force and second line
indication launch.
Other Income and Gains Other
income and gains for the three months and year ended
December 31, 2024, were $125.1 million and $173.1 million,
respectively, compared to $18.5 million and $58.1 million for the
three months and year ended December 31, 2023, respectively.
The increase of $106.6 million and $115.0 million for the three
months and year ended, respectively, were primarily attributable to
an increase in unrealized foreign exchange gains related to the
changes in the intercompany loan balances and cash balances as a
result of exchange rate changes between USD and Euro.
Other ExpensesFor the three
months and year ended December 31, 2024, there were no
expenses, compared to $38.4 million and $28.5 million for the three
months and year ended December 31, 2023. The decrease of $38.4
million and $28.5 million for the three months and year ended,
respectively, were primarily due to unrealized foreign currency
exchange loss related to the changes in the intercompany loan
balances and cash balances as a result of exchange rate changes
between USD and Euro.
Net income or loss for the
PeriodFor the three months ended December 31, 2024,
net income was $26.3 million, or $0.07 per share, compared to a net
loss of $144.8 million, or $0.40 per share, for the three months
ended December 31, 2023. The increase of $171.1 million for
the three months ended was primarily attributable to unrealized
foreign currency exchange gains due to changes in the intercompany
loan balances and cash balances as a result of exchange rate
changes between USD and Euro. For the year ended December 31,
2024, net loss was $177.0 million, or $0.48 per share, compared to
a net loss of $518.3 million, or $1.47 per share, for the year
ended December 31, 2023.
Adjusted Net Loss for the
PeriodAdjusted net loss for the three months ended
December 31, 2024 was $59.1 million, or an adjusted net loss
of $0.16 per share, compared to an adjusted net loss of $88.5
million, or an adjusted net loss of $0.24 per share, for the three
months ended December 31, 2023. For the year ended
December 31, 2024, adjusted net loss was $188.8 million, or an
adjusted net loss of $0.52 per share, compared to an adjusted net
loss $335.7 million, or an adjusted net loss of $0.95 per share,
for the year ended December 31, 2023.
Webcast/Conference Call Details:Legend Biotech
will host its quarterly earnings call and webcast today at 8:00am
ET. To access the webcast, please visit this weblink.
A replay of the webcast will be available on Legend Biotech’s
website at
https://investors.legendbiotech.com/events-and-presentations.
About Legend BiotechWith over
2,500 employees, Legend Biotech is the largest standalone
cell therapy company and a pioneer in treatments that change cancer
care forever. The company is at the forefront of the CAR-T cell
therapy revolution with CARVYKTI®, a one-time treatment for
relapsed or refractory multiple myeloma, which it develops and
markets with collaborator Johnson & Johnson. Centered in the
US, Legend is building an end-to-end cell therapy company by
expanding its leadership to maximize CARVYKTI’s patient access and
therapeutic potential. From this platform, the company plans to
drive future innovation across its pipeline of cutting-edge cell
therapy modalities.
Learn more at https://legendbiotech.com and
follow us on X (formerly Twitter) and LinkedIn.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTSStatements in this press release
about future expectations, plans and prospects, as well as any
other statements regarding matters that are not historical facts,
constitute “forward-looking statements” within the meaning of The
Private Securities Litigation Reform Act of 1995. These statements
include, but are not limited to, statements relating to Legend
Biotech’s strategies and objectives; statements relating to
CARVYKTI® including Legend Biotech’s expectations for CARVYKTI® and
its therapeutic potential; statements related to Legend Biotech
manufacturing expectations for CARVYKTI®, statements related to
Legend Biotech’s ability to fund its operations into 2026 and
Legend Biotech’s anticipated achievement of operating profit
excluding unrealized foreign exchange gains or losses in 2026;
statements related to Legend Biotech’s ability to achieve operating
profit; and the potential benefits of Legend Biotech’s product
candidates. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and
similar expressions are intended to identify forward- looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Legend Biotech’s expectations could be
affected by, among other things, uncertainties involved in the
development of new pharmaceutical products; unexpected clinical
trial results, including as a result of additional analysis of
existing clinical data or unexpected new clinical data; unexpected
regulatory actions or delays, including requests for additional
safety and/or efficacy data or analysis of data, or government
regulation generally; unexpected delays as a result of actions
undertaken, or failures to act, by our third party partners;
uncertainties arising from challenges to Legend Biotech’s patent or
other proprietary intellectual property protection, including the
uncertainties involved in the U.S. litigation process; government,
industry, and general product pricing and other political
pressures; as well as the other factors discussed in the “Risk
Factors” section of Legend Biotech’s Annual Report on Form 20-F for
the year ended December 31, 2024 filed with the Securities and
Exchange Commission (SEC) on March 11, 2025 and Legend Biotech’s
other filings with the SEC. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those described
in this press release as anticipated, believed, estimated or
expected. Any forward-looking statements contained in this press
release speak only as of the date of this press release. Legend
Biotech specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
INVESTOR CONTACT:Jessie YeungTel: (732)
956-8271jessie.yeung@legendbiotech.com
PRESS CONTACT:Mary Ann OndishTel: (914)
552-4625media@legendbiotech.com
| |
|
|
|
LEGEND BIOTECH CORPORATIONCONDENSED
CONSOLIDATED STATEMENTS OF PROFIT OR
LOSS(UNAUDITED) |
| |
|
|
| |
Three Months Ended December
31, |
|
Year Ended December 31, |
| |
2024 |
|
2023 |
|
2024 |
|
2023 |
| US$’000, except share
and per share data |
|
|
|
|
|
|
|
| REVENUE |
|
|
|
|
|
|
|
|
License revenue |
18,281 |
|
|
— |
|
|
138,404 |
|
|
35,160 |
|
|
Collaboration revenue |
168,017 |
|
|
79,435 |
|
|
482,580 |
|
|
249,804 |
|
|
Other revenue |
224 |
|
|
29 |
|
|
6,257 |
|
|
179 |
|
|
Total revenue |
186,522 |
|
|
79,464 |
|
|
627,241 |
|
|
285,143 |
|
| Cost of collaboration
revenue |
(69,399 |
) |
|
(32,450 |
) |
|
(216,365 |
) |
|
(144,214 |
) |
| Cost of license and other
revenue |
(4,523 |
) |
|
— |
|
|
(18,216 |
) |
|
— |
|
| Research and development
expenses |
(104,432 |
) |
|
(105,683 |
) |
|
(413,544 |
) |
|
(382,218 |
) |
| Administrative expenses |
(34,201 |
) |
|
(28,707 |
) |
|
(136,783 |
) |
|
(106,769 |
) |
| Selling and distribution
expenses |
(48,925 |
) |
|
(33,677 |
) |
|
(147,481 |
) |
|
(94,158 |
) |
| Other income and gains |
125,056 |
|
|
18,450 |
|
|
173,093 |
|
|
58,126 |
|
| Other expenses |
(12 |
) |
|
(38,389 |
) |
|
(40 |
) |
|
(28,484 |
) |
| Fair value loss of warrant
liability |
— |
|
|
— |
|
|
— |
|
|
(85,750 |
) |
| Loss on Asset Impairment |
(4,423 |
) |
|
— |
|
|
(4,423 |
) |
|
— |
|
| Finance costs |
(5,152 |
) |
|
(5,820 |
) |
|
(21,615 |
) |
|
(21,794 |
) |
| INCOME (LOSS) BEFORE TAX |
40,511 |
|
|
(146,812 |
) |
|
(158,133 |
) |
|
(520,118 |
) |
| Income tax
(expense)/benefit |
(14,227 |
) |
|
1,994 |
|
|
(18,893 |
) |
|
1,864 |
|
| NET INCOME (LOSS) FOR THE
PERIOD |
26,284 |
|
|
(144,818 |
) |
|
(177,026 |
) |
|
(518,254 |
) |
| Attributable to: |
|
|
|
|
|
|
|
|
Ordinary equity holders of the parent |
26,284 |
|
|
(144,818 |
) |
|
(177,026 |
) |
|
(518,254 |
) |
| NET INCOME (LOSS) PER SHARE
ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT |
|
|
|
|
|
|
|
| Basic |
0.07 |
|
|
(0.40 |
) |
|
(0.48 |
) |
|
(1.47 |
) |
| Diluted |
0.07 |
|
|
(0.40 |
) |
|
(0.48 |
) |
|
(1.47 |
) |
| ORDINARY SHARES USED IN NET
INCOME (LOSS) PER SHARE COMPUTATION |
|
|
|
|
|
|
|
| Basic |
366,648,551 |
|
|
363,655,317 |
|
|
365,702,143 |
|
|
352,165,418 |
|
| Diluted |
402,806,991 |
|
|
363,655,317 |
|
|
365,702,143 |
|
|
352,165,418 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
LEGEND BIOTECH CORPORATIONCONDENSED
CONSOLIDATED STATEMENTS OF FINANCIAL
POSITION(UNAUDITED) |
|
|
|
|
|
|
|
| |
December 31, 2024 |
|
December 31, 2023 |
| |
US$’000 |
|
US$’000 |
| NON-CURRENT ASSETS |
|
|
|
|
|
| Property, plant and
equipment |
99,288 |
|
|
108,725 |
|
| Advance payments for property,
plant and equipment |
374 |
|
|
451 |
|
| Right-of-use assets |
101,932 |
|
|
80,502 |
|
| Time deposits |
4,362 |
|
|
4,362 |
|
| Intangible assets |
2,160 |
|
|
4,061 |
|
| Collaboration prepaid
leases |
172,064 |
|
|
151,216 |
|
| Other non-current assets |
6,056 |
|
|
1,493 |
|
| Total non-current assets |
386,236 |
|
|
350,810 |
|
| CURRENT ASSETS |
|
|
|
|
|
| Collaboration inventories,
net |
23,903 |
|
|
19,433 |
|
| Trade receivables |
6,287 |
|
|
100,041 |
|
| Prepayments, other receivables
and other assets |
130,975 |
|
|
69,251 |
|
| Financial assets at fair value
through profit or loss |
— |
|
|
663 |
|
| Pledged deposits |
70 |
|
|
357 |
|
| Time deposits |
835,934 |
|
|
30,341 |
|
| Cash and cash equivalents |
286,749 |
|
|
1,277,713 |
|
| Total current assets |
1,283,918 |
|
|
1,497,799 |
|
| Total assets |
1,670,154 |
|
|
1,848,609 |
|
| CURRENT LIABILITIES |
|
|
|
|
|
| Trade payables |
38,594 |
|
|
30,655 |
|
| Other payables and
accruals |
166,180 |
|
|
122,307 |
|
| Government grants |
532 |
|
|
68 |
|
| Lease liabilities |
4,794 |
|
|
3,175 |
|
| Tax payable |
20,671 |
|
|
7,203 |
|
| Contract liabilities |
46,874 |
|
|
53,010 |
|
| Total current liabilities |
277,645 |
|
|
216,418 |
|
| NON-CURRENT LIABILITIES |
|
|
|
|
|
| Collaboration interest-bearing
advanced funding |
301,196 |
|
|
281,328 |
|
| Lease liabilities long
term |
44,613 |
|
|
44,169 |
|
| Government grants |
6,154 |
|
|
7,305 |
|
| Contract liabilities |
— |
|
|
47,962 |
|
| Other non-current
liabilities |
— |
|
|
56 |
|
| Total non-current
liabilities |
351,963 |
|
|
380,820 |
|
| Total liabilities |
629,608 |
|
|
597,238 |
|
| EQUITY |
|
|
|
|
|
| Share capital |
37 |
|
|
36 |
|
| Reserves |
1,040,509 |
|
|
1,251,335 |
|
| Total ordinary shareholders’
equity |
1,040,546 |
|
|
1,251,371 |
|
| Total equity |
1,040,546 |
|
|
1,251,371 |
|
| Total liabilities and
equity |
1,670,154 |
|
|
1,848,609 |
|
| |
|
|
|
|
|
|
LEGEND BIOTECH CORPORATIONCONDENSED
CONSOLIDATED STATEMENTS OF CASH
FLOW(UNAUDITED) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Three Months Ended December 31, |
|
Year Ended December 31, |
| US$’000 |
2024 |
|
2023 |
|
2024 |
|
2023 |
| |
|
|
|
|
|
|
|
|
|
|
|
| INCOME (LOSS) BEFORE TAX |
40,511 |
|
|
(146,812 |
) |
|
(158,133 |
) |
|
(520,118 |
) |
| CASH FLOWS (USED IN) OPERATING
ACTIVITIES |
(82,078 |
) |
|
(95,645 |
) |
|
(144,033 |
) |
|
(393,276 |
) |
| CASH FLOWS (USED IN)/PROVIDED
BY INVESTING ACTIVITIES |
(87,842 |
) |
|
407,509 |
|
|
(850,544 |
) |
|
92,786 |
|
| CASH FLOWS (USED IN)/PROVIDED
BY FINANCING ACTIVITIES |
(333 |
) |
|
925 |
|
|
5,698 |
|
|
791,490 |
|
| NET (DECREASE)/INCREASE IN
CASH AND CASH EQUIVALENTS |
(170,253 |
) |
|
312,789 |
|
|
(988,879 |
) |
|
491,000 |
|
| Effect of foreign exchange
rate changes, net |
(2,275 |
) |
|
1,454 |
|
|
(2,085 |
) |
|
682 |
|
| Cash and cash equivalents at
beginning of the period |
459,277 |
|
|
963,470 |
|
|
1,277,713 |
|
|
786,031 |
|
| |
|
|
|
|
|
|
|
| CASH AND CASH EQUIVALENTS AT
END OF THE YEAR |
286,749 |
|
|
1,277,713 |
|
|
286,749 |
|
|
1,277,713 |
|
| ANALYSIS OF BALANCES OF CASH
AND CASH EQUIVALENTS |
|
|
|
|
|
|
|
| Cash and bank balances |
1,127,115 |
|
|
1,312,773 |
|
|
1,127,115 |
|
|
1,312,773 |
|
| Less: Pledged deposits |
70 |
|
|
357 |
|
|
70 |
|
|
357 |
|
| Time deposits |
840,296 |
|
|
34,703 |
|
|
840,296 |
|
|
34,703 |
|
| Cash and cash equivalents as
stated in the statement of financial position |
286,749 |
|
|
1,277,713 |
|
|
286,749 |
|
|
1,277,713 |
|
| Cash and cash equivalents as
stated in the statement of cash flows |
286,749 |
|
|
1,277,713 |
|
|
286,749 |
|
|
1,277,713 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
RECONCILIATION OF IFRS TO NON-IFRS MEASURES
We use Adjusted Net Loss and Adjusted Net Loss
per Share (which we sometimes refer to as “ANI per Share”) as
performance metrics. Adjusted Net Loss and ANI per Share are not
defined under IFRS, are not a measure of operating income,
operating performance, or liquidity presented in accordance with
IFRS, and are subject to important limitations. Our use of Adjusted
Net Loss has limitations as an analytical tool, and you should not
consider it in isolation or as a substitute for analysis of our
results as reported under IFRS. For example:
- Although depreciation and
amortization are non-cash charges, the assets being depreciated and
amortized may have to be replaced in the future, and Adjusted Net
Loss does not reflect cash capital expenditure requirements for
such replacements or for new capital expenditure requirements.
- Adjusted Net Income (Loss) excludes
unrealized foreign exchange gain (loss) which was primarily
resulted from changes in the intercompany loan balances and cash
balances as a result of exchange rate changes between USD and
EURO.
- Adjusted Net Loss does not reflect
changes in, or cash requirements for, our working capital
needs.
- In addition, Adjusted Net Loss
excludes such as share based compensation expense, which has been,
and will continue to be for the foreseeable future, a significant
recurring expense for our business and an important part of our
compensation strategy.
Also, our definition of Adjusted Net Loss and
Adjusted Net Loss per Share may not be the same as similarly titled
measures used by other companies.
However, we believe that providing information
concerning Adjusted Net Loss and Adjusted Net Loss per Share
enhances an investor’s understanding of our financial performance.
We use Adjusted Net Loss as a performance metric that guides
management in its operation of and planning for the future of the
business. We believe that Adjusted Net Loss provides a useful
measure of our operating performance from period to period by
excluding certain items that we believe are not representative of
our core business. We define Adjusted Net Loss as net loss adjusted
for (1) non-cash items such as depreciation and amortization, share
based compensation, impairment loss and fair value loss of warrant
liability and (2) unrealized foreign exchange gain or loss mainly
related to intercompany loan balances and cash deposit balances as
a result of exchange rate changes between USD and EUR.
Adjusted Net Loss per Share is computed by
dividing Adjusted Net Loss by the weighted average shares
outstanding.
| |
|
|
|
|
LEGEND BIOTECH CORPORATIONRECONCILIATION
OF IFRS TO NON-IFRS(UNAUDITED) |
| |
|
|
|
|
|
|
Three Months Ended December 31, |
Year Ended December 31, |
|
US$’000 |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
| |
|
|
|
|
|
|
|
|
|
Net Income (Loss) |
|
26,284 |
|
|
(144,818 |
) |
|
(177,026 |
) |
|
(518,254 |
) |
| Depreciation and
amortization |
|
6,796 |
|
|
5,351 |
|
|
23,359 |
|
|
20,451 |
|
| Share based compensation |
|
13,388 |
|
|
12,589 |
|
|
68,941 |
|
|
47,680 |
|
| Impairment loss |
|
4,423 |
|
|
— |
|
|
4,423 |
|
|
— |
|
| Unrealized foreign exchange
(gain)/loss (included in Other Expenses, other income and
gains) |
|
(109,975 |
) |
|
38,332 |
|
|
(108,509 |
) |
|
28,645 |
|
| Fair value loss of warrant
liability |
|
— |
|
|
— |
|
|
— |
|
|
85,750 |
|
| Adjusted net loss |
|
(59,084 |
) |
|
(88,546 |
) |
|
(188,812 |
) |
|
(335,728 |
) |
| |
|
|
|
|
|
|
|
|
| ANI per
share: |
|
|
|
|
|
|
|
|
| ANI per share - basic |
|
(0.16 |
) |
|
(0.24 |
) |
|
(0.52 |
) |
|
(0.95 |
) |
| ANI per share - diluted |
|
(0.15 |
) |
|
(0.24 |
) |
|
(0.52 |
) |
|
(0.95 |
) |
| |
|
|
|
|
|
|
|
|
Legend Biotech (NASDAQ:LEGN)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Legend Biotech (NASDAQ:LEGN)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025
